Trial Profile
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 03 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 18 Oct 2022 Results published in the Journal of Clinical Oncology